LUNG — Pulmonx Corp

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Pulmonx Corp

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$1.57
Market Cap$65.0M
Float37.3M
Shares Outstanding42.2M
P/E (Forward)28.33
Price/Sales (TTM)0.73
vs. Analyst Target+229.1% to analyst PT
Profit Margin-60.09%
Operating Margin (TTM)-62.94%
Revenue (TTM)$88.5M
Dividend RateNone
Analyst Target Price$5.17 (7 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $32.7M -$32.2M $21.2M -$28.4M
2021 $48.4M -$48.7M $35.6M -$46.6M
2022 $53.7M -$58.9M $39.9M -$56.0M
2023 $68.7M -$60.8M $50.8M -$55.1M
2024 $83.8M -$56.4M $62.0M -$50.8M
2025 $90.5M -$54.0M $67.1M -$52.6M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $23.9M -$15.2M
Sep 2025 $21.5M -$14.0M
Dec 2025 $22.6M -$10.4M
Mar 2026 $20.6M -$13.7M

Ownership & Float

Insider Ownership4.7%
Institutional Ownership79.1%
Short Float9.6%
% of All Funds Holding1.24%
Number of Funds Holding102

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$1.36Near-term / short-term trend
Weekly40-Week SMA$1.68Medium-term trend
Weekly80-Week SMA$3.34Cyclical trend (business cycle)
Weekly200-Week SMA$7.60Secular trend (multi-year)
Monthly10-Month SMA$1.65Near-term monthly trend
Monthly20-Month SMA$3.49Medium-term monthly trend
Monthly40-Month SMA$6.79Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.50 resistance 1.92x 9 months ago
$3.10 resistance 1.10x 10 months ago
$5.20 resistance 1.48x 11 months ago
$6.70 resistance 1.26x 12 months ago
$9.20 resistance 1.66x 24 months ago

Historical Earnings Reactions (23 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 2.10% -0.08% 47.83% 39.73% -36.83%
1 Day -1.87% -0.43% 47.83% 32.23% -60.94%
1 Week -4.51% -2.00% 47.83% 30.02% -48.57%
2 Weeks -6.90% -6.58% 39.13% 33.97% -52.06%
1 Month -11.60% -10.08% 27.27% 27.97% -50.08%

Next earnings: July 18, 2026 (52 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.34% 47.7% 264
Tuesday 0.19% 51.5% 293
Wednesday 0.05% 43.3% 291
Thursday -0.56% 42.4% 283
Friday 0.15% 50.2% 285

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 79.1%

Insider Transactions — Smart Summary

Total insider ownership: 4.7%

12-Month Insider Activity Summary

Total Filings18
Net Value-$345,412.237
Net Shares Change1,424,046
% of Float3.8%
C-Suite Filings15
Clusters Detected4

Key Insiders

NameTitleNet ValueFilingsActivity
French Glendon E. III President and CEO -$110,796.44 2 2 sell
Florin Daniel P +$71,362.26 1 1 buy
Lehman David Aaron GENERAL COUNSEL -$49,265.77 3 3 sell
Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER -$20,982.3 2 2 sell
Williamson Steven S. PRESIDENT AND CEO -$15,436.8 1 1 sell
Radhakrishnan Srikanth Chief Science andTechn. Officer -$14,990.69 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-06-04 – 2025-06-13 6 6 -$64,691.577 4 C-suite
2025-09-03 – 2025-09-03 4 4 -$54,233.6 4 C-suite
2025-12-02 – 2025-12-09 4 4 -$86,294.64 3 C-suite
2026-03-04 – 2026-03-04 4 4 -$140,518.95 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-04 Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER -$11,056.76 Transaction at $1.43, now +9.8%
2026-03-04 Radhakrishnan Srikanth Chief Science andTechn. Officer -$14,990.69 Transaction at $1.43, now +9.8%
2026-03-04 Lehman David Aaron GENERAL COUNSEL -$17,498.91 Transaction at $1.43, now +9.8%
2026-03-04 French Glendon E. III President and CEO -$96,972.59 Transaction at $1.43, now +9.8%
2025-12-02 French Glendon E. III President and CEO -$13,823.85 Transaction at $1.57, now +0.0%
2025-06-05 Florin Daniel P +$71,362.26 Transaction at $3.06, now -48.7%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Pulmonx Corp (LUNG) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for LUNG on Trend Edge →